Contraline: The $92.5M Bet That Men Will Finally Own Their Birth Control
Big Pharma walked away from half the global population. A scrappy biotech just picked up the check.
Company Overview
What Contraline Actually Does
Contraline, Inc. is a clinical-stage biopharmaceutical company headquartered in Charlottesville, Virginia. It’s building what could become the first approved pharmacological contraceptive for men. The company has two investigational products in active clinical development: NES/T Gel and ADAM.
On June 2, 2026, Contraline closed a $92.5 million Series B, co-led by BVF Partners and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other investors. The round funds Phase 3 readiness for NES/T and continued advancement of ADAM.
The company was co-founded by Kevin Eisenfrats, who serves as CEO. Eisenfrats has been building in men’s reproductive health since his undergraduate days at the University of Virginia, where the core concept behind ADAM was first developed. He’s not a career biotech executive who wandered into a hot category — he identified the unmet need, raised early capital from GV, ran first-in-human trials in Australia, and is now steering a late-stage clinical program backed by some of the sharpest life sciences investors in the business. Iris van Alderwerelt van Rosenburgh from BVF Partners joins the board alongside the Series B close.
The two investigational male contraceptive products:
NES/T Gel — a daily hormonal topical gel combining Nestorone (a progestin) with testosterone. Suppresses sperm production while maintaining physiological testosterone levels, avoiding the side effects that tanked prior hormonal male contraceptive programs. Licensed from the Population Council and the NIH’s NICHD. Phase 2b completed, enrolling 462 couples globally. Phase 3 start projected for 2027.
ADAM — a non-hormonal injectable hydrogel implanted into the vas deferens via a minimally invasive procedure. Physically blocks sperm transport and is designed to eventually biodegrade, making it reversible. First-in-human trial completed across three Australian sites. 25 participants enrolled, 100% successful implantation rate. 24-month efficacy data shows azoospermia in participants who’ve reached that milestone. Phase 2 now in planning.
This is Startup Spotlight. Every week I break down a company worth watching. Subscribe for $7.99/mo to get the full analysis.
